Polymorphisms in Nanog Are Associated with Oral Leukoplakia: Case-control Study

Overview

Journal Odontology

Specialty Dentistry

Date 2024 Dec 23

PMID 39714583

Authors

Arieli Carini Michels

Suelen Teixeira Scheifer

Fernanda Tiboni

Filipe Modolo

Emanuela Carla Dos Santos

Rafaela Scariot

Maria Cassia Ferreira Aguiar

Sergio Aparecido Ignacio

Lucia de Noronha

Mariana Hornung Marins

Bruno Correia Jham

Cleber Machado de Souza

Aline Cristina Batista Rodrigues Johann

Affiliations

Soon will be listed here.

Abstract

To investigate the association of NANOG polymorphisms with oral leukoplakia. In this case-control study, 68 cases of oral leukoplakia, and 21 of normal oral mucosa (control) were submitted to genotyping of tagSNPs polymorphisms: rs877716 and rs10845877 in NANOG, through real-time polymerase chain reaction (PCR). Pearson's chi-squared and Fisher's exact statistical tests were used, with a significance of 5%. For the dominant genetic model of the G allele of rs877716, the genotypes AG + GG revealed higher frequency in subjects in the oral leukoplakia group than in control subjects (75,4 and 50% respectively; p = 0,031). Subjects with this genotype were 3,063 times more likely to develop oral leukoplakia compared to subjects with AA. In the allelic genetic model, for rs10845877, the C allele was more frequent in subjects with leukoplakia than in control subjects (25 and 7, 5% respectively; p = 0, 01). There was no association found in the other genetic models. Polymorphisms in NANOG are associated with oral leukoplakia.

References

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

Warnakulasuriya S, Ariyawardana A . Malignant transformation of oral leukoplakia: a systematic review of observational studies. J Oral Pathol Med. 2015; 45(3):155-66. DOI: 10.1111/jop.12339. View

Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E . Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med. 2008; 37(3):127-33. DOI: 10.1111/j.1600-0714.2007.00584.x. View

Shridhar K, Aggarwal A, Walia G, Gulati S, Geetha A, Prabhakaran D . Single nucleotide polymorphisms as markers of genetic susceptibility for oral potentially malignant disorders risk: Review of evidence to date. Oral Oncol. 2016; 61:146-51. PMC: 5046699. DOI: 10.1016/j.oraloncology.2016.08.005. View

Reers S, Pfannerstill A, Maushagen R, Pries R, Wollenberg B . Stem cell profiling in head and neck cancer reveals an Oct-4 expressing subpopulation with properties of chemoresistance. Oral Oncol. 2014; 50(3):155-62. DOI: 10.1016/j.oraloncology.2013.12.006. View

Capp J . Cancer Stem Cells: From Historical Roots to a New Perspective. J Oncol. 2019; 2019:5189232. PMC: 6594320. DOI: 10.1155/2019/5189232. View

Jeter C, Yang T, Wang J, Chao H, Tang D . Concise Review: NANOG in Cancer Stem Cells and Tumor Development: An Update and Outstanding Questions. Stem Cells. 2015; 33(8):2381-90. PMC: 4509798. DOI: 10.1002/stem.2007. View

Lee H, Kang Y, Lee J, Byun J, Kim U, Jang S . Positive expression of NANOG, mutant p53, and CD44 is directly associated with clinicopathological features and poor prognosis of oral squamous cell carcinoma. BMC Oral Health. 2015; 15(1):153. PMC: 4667499. DOI: 10.1186/s12903-015-0120-9. View

Zhang L, Poh C, Williams M, Laronde D, Berean K, Gardner P . Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila). 2012; 5(9):1081-9. PMC: 3793638. DOI: 10.1158/1940-6207.CAPR-12-0173. View

10.

Qiao B, He B, Cai J, Yang W . The expression profile of Oct4 and Sox2 in the carcinogenesis of oral mucosa. Int J Clin Exp Pathol. 2014; 7(1):28-37. PMC: 3885457. View

11.

Watanabe M, Ohnishi Y, Inoue H, Wato M, Tanaka A, Kakudo K . NANOG expression correlates with differentiation, metastasis and resistance to preoperative adjuvant therapy in oral squamous cell carcinoma. Oncol Lett. 2013; 7(1):35-40. PMC: 3861537. DOI: 10.3892/ol.2013.1690. View

12.

Kitahara A, Michels A, Luiz S, Nagashima S, Martins A, de Azevedo M . Immunohistochemical detection of NANOG in oral leukoplakia. Oral Dis. 2021; 29(2):376-379. DOI: 10.1111/odi.13891. View

13.

Wang D, Sadee W . Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). AAPS J. 2006; 8(3):E515-20. PMC: 2761059. DOI: 10.1208/aapsj080361. View

14.

Howard J, Masterson L, Dwivedi R, Riffat F, Benson R, Jefferies S . Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small-volume primary oropharyngeal carcinoma. Cochrane Database Syst Rev. 2016; 12:CD010963. PMC: 6463943. DOI: 10.1002/14651858.CD010963.pub2. View

15.

Nigam K, Yadav S, Samadi F, Bhatt M, Gupta S, Sanyal S . Risk Modulation of Oral Pre Cancer and Cancer with Polymorphisms in XPD and XPG Genes in North Indian Population. Asian Pac J Cancer Prev. 2019; 20(8):2397-2403. PMC: 6852806. DOI: 10.31557/APJCP.2019.20.8.2397. View

16.

Rao A, Parameswar P, Majumdar S, Uppala D, Kotina S, Vennamaneni N . Evaluation of Genetic Polymorphisms in Glutathione S-Transferase Theta1, Glutathione S-Transferase Mu1, and Glutathione S-Transferase Mu3 in Oral Leukoplakia and Oral Squamous Cell Carcinoma with Deleterious Habits using Polymerase Chain Reaction. Int J Appl Basic Med Res. 2017; 7(3):181-185. PMC: 5590381. DOI: 10.4103/ijabmr.IJABMR_58_16. View

17.

Tulsyan S, Agarwal G, Lal P, Mittal B . Significant association of combination of OCT4, NANOG, and SOX2 gene polymorphisms in susceptibility and response to treatment in North Indian breast cancer patients. Cancer Chemother Pharmacol. 2014; 74(5):1065-78. DOI: 10.1007/s00280-014-2588-4. View

18.

Espinosa Angarica V, Sol A . Bioinformatics Tools for Genome-Wide Epigenetic Research. Adv Exp Med Biol. 2017; 978:489-512. DOI: 10.1007/978-3-319-53889-1_25. View